A selection of recent neurology papers is summarized and discussed, with a focus on review articles and those that have the potential to change clinical practice. Please note that AI has been used in generating the content.
Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology
Claim This Podcastby Amer Ghavanini
200 episodes
Updated Daily
Accepts GuestsHas Sponsors
Podcast Overview
A selection of recent neurology papers is summarized and discussed, with a focus on review articles and those that have the potential to change clinical practice. Please note that AI has been used in generating the content.
Language
🇺🇲
Publishing Since
12/29/2024
1 verified contact email on file for Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 14, 2026
Drugs for Migraine Prophylaxis
<p>This medical review examines current pharmacological strategies for <strong>migraine prophylaxis</strong>, distinguishing between <strong>episodic</strong> and <strong>chronic</strong> forms of the condition. The authors evaluate traditional oral therapies such as <strong>beta-blockers</strong>, <strong>topiramate</strong>, and <strong>amitriptyline</strong>, noting that while effective for episodic cases, they often carry significant side effects. A major focus is placed on recent therapeutic advancements, specifically <strong>monoclonal antibodies</strong> and <strong>gepants</strong> that target the <strong>CGRP</strong> pathway. These newer treatments demonstrate high tolerability and effectiveness, even for patients suffering from <strong>medication overuse headache</strong> or those who failed previous therapies. Additionally, <strong>onabotulinumtoxinA</strong> is highlighted as a proven option specifically for chronic migraine management. The text concludes that these modern interventions offer a superior safety profile and rapid onset of action compared to conventional medications.</p>
June 7, 2026
Intrathecal Mesenchymal Stem Cells in Progressive MS: The SMART-MS Trial
<p>This <strong>randomized, double-blind study</strong> investigated the potential for <strong>autologous mesenchymal stem cells (MSCs)</strong> to repair neurological damage in patients with <strong>progressive multiple sclerosis</strong>. Using an <strong>intrathecal administration</strong> route to bypass the blood-brain barrier, researchers monitored <strong>nerve conduction speeds</strong> and brain volume changes over a year. The results failed to demonstrate a significant <strong>neuroregenerative effect</strong>, as the primary measures of electrical signal latency showed no improvement compared to the placebo group. While <strong>cerebrospinal fluid proteomics</strong> suggested some anti-inflammatory activity, these molecular shifts were overshadowed by <strong>safety concerns</strong>, including localized spinal inflammation and nerve root clumping. Ultimately, the trial concluded that this specific stem cell therapy does not currently provide a viable solution for <strong>functional repair</strong> in MS. The authors suggest that future applications of this delivery method must be approached with <strong>extreme caution</strong> due to the risk of serious adverse events.</p>
May 31, 2026
Neurologic Adverse Events from Immune Checkpoint Inhibitors
<p>Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment, but they can trigger a wide range of <strong>neurological immune-related adverse events</strong> (irAE) by disrupting immune tolerance. These complications affect both the <strong>central and peripheral nervous systems</strong>, often manifesting with rapid progression and significant risks of disability or death. A particularly critical condition highlighted is <strong>Triple M syndrome</strong>, which involves the life-threatening triad of myasthenia, myositis, and myocarditis. Diagnostic challenges arise because these events often present with <strong>atypical symptoms</strong>, necessitating a protocol of excluding other causes while confirming neuroinflammation through laboratory and radiological data. Because many of these neurological events are <strong>resistant to standard corticosteroids</strong>, there is a growing emphasis on early intervention with <strong>targeted biologics</strong> and immunomodulatory therapies. Future medical research aims to improve patient outcomes by identifying <strong>predictive biomarkers</strong> and refining risk stratification, particularly for vulnerable populations with pre-existing autoimmune conditions.</p>
200 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Continuum Audio
American Academy of Neurology
Neurology® Podcast
American Academy of Neurology
The Cabral Concept
Dr. Stephen Cabral
Decoding Sjogren’s Disease: A Clinical Deep Dive
Health Monitor Network
The Dr. Brighten Show
Dr. Jolene Brighten
The Clinical Problem Solvers
The Clinical Problem Solvers
JAMA Clinical Reviews
JAMA Network
Practical Neurology Podcast
BMJ Group
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
NEJM This Week
NEJM Group
Neurology Minute
American Academy of Neurology
Sjogren's Strong
Sitch Radio
Feel Better, Live More with Dr Rangan Chatterjee
Dr Rangan Chatterjee: GP & Author
NEI Podcast
Neuroscience Education Institute
OrphaChat — a Rare Disease Podcast
Robin Hendel, MD
Deep-dive analytics for Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.